Information Provided By:
Fly News Breaks for October 24, 2019
Oct 24, 2019 | 16:17 EDT
As previously reported, Cantor Fitzgerald analyst Brandon Folkes initiated coverage of MannKind (MNKD) with an Overweight rating and $3.00 price target. Initial expectations for Afrezza, the company's inhaled insulin, were unrealistic, but he believes expectations have been adequately reset, Folkes said. Since receiving Afrezza back from Sanofi (SNY), uptake has been steadily gaining traction, the analyst added.
News For MNKD From the Last 2 Days
There are no results for your query MNKD